FDA Approval for Pediatric CD22-Positive B-Cell ALL
6th March 2024: Inotuzumab ozogamicin (Besponsa, Pfizer) has been granted approval by the Food and Drug Administration for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in pediatric patients aged 1 year and above.
The effectiveness of the treatment was assessed in a research conducted at multiple centers, involving 53 pediatric patients aged 1 year and older who had relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL). The study assessed two different dose levels: an initial dose of 1.4 mg/m2/cycle in 12 individuals and a dose of 1.8 mg/m2/cycle in 41 participants. The premedications administered were methylprednisolone at a dosage of 1 mg per kilogram (with a maximum limit of 50 mg), an antipyretic, and an antihistamine. The patients underwent a median of 2 cycles of therapy, with a range of 1 to 4 cycles.
The primary endpoints of effectiveness were complete remission (CR), the length of time that CR lasted, and the percentage of patients who had a complete remission with no detectable minimal residual disease (MRD) present. Complete remission (CR) was characterized by the presence of less than 5% blasts in the bone marrow and the absence of leukemia blasts in the peripheral blood. Additionally, CR required the restoration of normal peripheral blood counts (platelets equal to or greater than 100 × 109 and absolute neutrophil count equal to or greater than 1 × 109/L), as well as the resolution of any extramedullary illness. Minimal residual disease (MRD) was characterized by the presence of leukemic cells accounting for less than 1 x 10-4 (less than 0.01%) of the total bone marrow nucleated cells, as determined by flow cytometry or PCR.
Among all patients, 22 out of 53 (42%, 95% CI: 28.1, 55.9%) achieved complete remission (CR), with a median period of 8.2 months (95% CI: 2.6, NE). The incidence of MRD negativity in patients with complete remission (CR) was 21 out of 22, which corresponds to 95.5% (95% confidence interval: 77.2, 99.9) according to flow cytometry. Based on RQ-PCR, the rate of MRD negativity was 19 out of 22, equivalent to 86.4% (95% confidence interval: 65.1, 97.1).
The predominant side effects (≥20%), encompassing test irregularities, were thrombocytopenia, pyrexia, anemia, vomiting, infection, bleeding, neutropenia, nausea, leukopenia, febrile neutropenia, elevated transaminases, stomach discomfort, and headache.
The first dose of inotuzumab ozogamicin for the first cycle is 1.8 mg/m2 per cycle. This dose should be given in three separate doses on Day 1 (0.8 mg/m2), Day 8 (0.5 mg/m2), and Day 15 (0.5 mg/m2). Cycle 1 has a period of 3 weeks, although it can be prolonged to 4 weeks if the patient achieves complete remission or complete remission with incomplete hematologic recovery, and/or to allow for recovery from toxicity. Refer to the prescribed directions for the recommended dosage following the initial cycle.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Dr. Nishant Mittal
Dr. Nishant Mittal is a highly accomplished researcher with over 13 years of experience in the fields of cardiovascular biology and cancer research. Significant contributions to stem cell biology, developmental biology, and innovative research techniques mark his career. Research Highlights Dr. Mittal's research has focused on several key areas: 1) Cardio…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.